Ipsen in the World

Choose your location:

Choose a Language

Contact us

Investors

As a global pharmaceutical company with a biotech mindset and a proven ability to provide new, life-changing therapies, Ipsen is a leading player in its core therapeutic areas.

Contact us

 

Craig Marks Adrien Dupin de Saint-Cyr
Vice President, Investor Relations Investor Relations Manager
+44 7584 349 193 +33 6 64 26 17 49

Contact us

Ipsen to acquire Epizyme, expanding its portfolio in oncology

 

Conference call

A conference call and webcast for investors and analysts will begin today at 2pm Paris time.

Participants can join the call by dialling +1 785 424 1876 or, for U.S. participants, +1 877 888 4312 toll-free;

the passcode is 63710.

 

Access to the webcast

Access to the presentation

Ipsen to acquire Epizyme, expanding its portfolio in oncology

Ipsen in Brief

Ipsen in Brief 2022

Discover Ipsen in two pages; our products and key figures, our objectives and our strategy.

Download

Registration document

2021 Universal Registration Document

This registration document contains forward-looking statements about Ipsen’s targets and forecasts, including the Annual Financial Report. The registration document provides a comprehensive information about the Company its activities, financial information, colleagues and legal information

Download

Stock information

Share price and stock information, benchmark, orders, transactions: find out Ipsen share-related data.

Ipsen shares
ADR program Shareholding structure Analyst coverage

ADR program

Ipsen established a sponsored level I American Depository Receipt (ADR) program in the United States in June 2010 with Deutsche Bank trust company Americas (Deutsche Bank).

  • Ticker: IPSEY
  • Structure: Sponsored Level I ADR
  • Exchange: OTC
  • Ratio (ORD:ADR): 1:4
  • ADR ISIN: US4626291060
  • ORD ISIN: FR0010259150

CONTACT DETAILS FOR ADR HOLDERS:

Deutsche Bank Shareholder Services
AST
Operations Center
6201 15th Avenue
Brooklyn, NY 11219
USA

Email:
Toll-free number: +1 (866) 706-0509
Direct Dial: +1 (718) 921-8137

The Company’s ADR program is sponsored by Deutsche Bank. As the depository bank Deutsche Bank performs the following roles for ADR holders:

  • Records and maintains the register of ADR holders
  • Is the stock transfer agent
  • Distributes dividends in U.S. dollars (if applicable)
  • Facilitates the proxy voting process and exercises the voting rights on behalf of ADR holders (if applicable)
  • Issues and cancels Ipsen ADSs (American Depository Shares)
  • Can distribute company circulars and Annual General Meeting documentation (if applicable)

For those holders who are not registered because their shares are held through a ‘Street name’ (nominee account), your nominee will receive company documents from time to time from Deutsche Bank to distribute to ADR holders. You need to make arrangements with your nominee if you wish to receive such documents and to be able to exercise your vote through the depositary bank at general meetings (if applicable).

Shareholding structure

Shareholder structure

Analyst coverage

Stock information

Research & Development pipeline

Ipsen R&D has a valuable pipeline encompassing both lifecycle management of our well-established products, and the development of innovative new molecules.

Learn more

We are focused on accelerating our sales growth while improving our profitability and cash flow generation, in order to further invest in business development to build an innovative and sustainable pipeline and to maintain the growth momentum of the business.


Aymeric Le Chatelier, CFO

Financial objectives and outlook

a

2022 financial objectives Mid-term financial outlook and capital-allocation strategy

2022 financial objectives

Ipsen has set its financial guidance for FY 2022, excluding any contribution from the CHC business:

  • Total-sales growth greater than 2.0%, at constant currency. Based on the level of exchange rates in Q1 2022, Ipsen anticipates an additional favorable impact of 2% from currencies  
  • Core operating margin greater than 35.0% of total sales, excluding any potential impact of incremental investments from future external-innovation transaction

This guidance incorporates expectations for Somatuline of further launches of generic lanreotide in other countries in the E.U., as well as increased competition in the U.S.

Mid-term financial outlook and capital-allocation strategy

Ipsen’s financial outlook for 2020-24 excludes any contribution from the CHC business:

  • Total-sales 2020-24 compound annual growth rate between +4% and +6% at constant currency and assuming risk-adjusted potential additional indications
  •  Continued commitment to invest in R&D supported by SG&A efficiencies:
    • Reduced SG&A expenses as a percentage of total sales, driven by further focus and optimization
    • Higher R&D expenses as a percentage of total sales, driven by the external-innovation strategy

To support the external-innovation strategy, Ipsen anticipates cumulative remaining firepower of €3.5bn by 2024, including the divestment of the CHC business. The calculation is based on net debt at 2.0 x EBITDA.

Financial objectives

2021 Integrated Annual Report

In 2021, we achieved incredible growth and change as we implemented our strategy; ‘Focus. Together. For Patients & Society.’ From growing our pipeline with external innovation to researching and developing new treatments, we’re proud of our progress and excited to go further in 2022.

Annual Report

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2022